Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Actuate Therapeutics, Inc. announced publication in Nature Medicine of Phase 2 clinical trial results showing that Elraglusib in combination with gemcitabine and nab-paclitaxel (GnP) chemotherapy significantly improved overall survival in patients with previously untreated metastatic pancreatic ductal adenocarcinoma compared to chemotherapy alone. …